



Roseman University of Health Sciences

Winter Therapeutics Continuing Professional Education Program

Activity Registration Fee: \$60.00

Name: _____ Email: _____

Address: _____ City: _____

State: _____ Zip code: _____ Phone: _____ NABP eProfile ID: _____

Date of birth (MMDD) _____

Program Location:

Program Schedule:

Saturday, February 25, 2012

3:00 p.m. – 7:30 p.m.

Utah State University

5005 Old Main Hill-

Eccles: Room 305

Logan, UT 84322-5005

3:00 pm – 4:00 pm

Law and Regulatory Topics Regarding Generics:
Challenges & Controversies

4:00 pm – 4:30 pm

Refreshments

4:30 pm – 7:30 pm

Lipid-based Cardiovascular Risk Reduction
Strategies: Reconciling Evidence-based practice
and personalized medicine.

Registration Information

1. **Register Online** at <https://www.regonline.com/winterther> to pay by credit card.
2. **To register by mail**, complete this form and mail it with a check made payable to
“Roseman University of Health Sciences” for the applicable amount to:
Continuing Professional Education Program, Roseman University College of Pharmacy
11 Sunset Way
Henderson, NV 89014

Target audience: pharmacists interested in improving their confidence in managing dyslipidemia. In addition, pharmacists interested in learning about regulatory issues affecting generics are also encouraged to attend. **This activity is not open to pharmacy technicians. Participants may not register on site on the day of the activity.** Registration for this program will close on Friday, February 17, 2012. A receipt will be sent via email upon receipt of payment and your registration form or following electronic registration. Greater than 10 days before the scheduled program, full refunds may be issued minus a 20% administrative fee. Less than or equal to 10 days before the scheduled program, no refund will be issued.

A medical education grant application has been submitted to support costs associated with this program.



Roseman University of Health Sciences College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a Provider of continuing pharmacy education. This program provides 3 hours (0.3 CEU) of application-based continuing education and 1 hour (0.1 CEU) of knowledge-based continuing education credit for a total of 4 hours (0.4 CEU) of continuing education credit after successful completion of each program post-test at the minimum proficiency level and the program evaluation. ACPE program numbers: 0455-0000-12-001-L04-P (Lipids), 0455-0000-12-002-L03-P (Law).

Statements of credit will be mailed or emailed within 30 days of program completion.

University of Southern Nevada is now Roseman University of Health Sciences.

Preceptor Code _____

Program Faculty

Tim Drake, Pharm.D., BCPS

Assistant Professor of Pharmacy Practice
Roseman University of Health Sciences
Clinical Ambulatory Pharmacist
McKay-Dee Hospital

Joanne LaFleur, Pharm.D., MSPH

Assistant Professor
University of Utah, College of Pharmacy

Learning Objectives

Law and Regulatory Topics Regarding Generics: Challenges & Controversies (0.1 CEU)

1. Discuss the generic approval process and the science behind establishing bioequivalence.
2. Explain federal regulations which have affected the availability of generics for biopharmaceutical agents.
3. Identify challenges associated with establishing bioequivalence with biopharmaceuticals.
4. Develop a communication plan for educating patients and providers about generic drugs.

Lipid-based Cardiovascular Risk Reduction Strategies: Reconciling Evidence-Based Practice and Personalized Medicine (0.3 CEU)

1. Identify risk factors for coronary artery disease.
2. Determine a patient's 10-year risk of developing coronary artery disease.
3. Using NCEP ATP III guidelines, determine a patient's LDL goal based on their risk factors, 10-year risk and past medical history.
4. Differentiate between primary and secondary prevention.
5. Recite goals for HDL cholesterol, triglycerides and total cholesterol.
6. For each class of medications used to treat dyslipidemia, identify important monitoring parameters, dosing considerations and efficacy.
7. Appropriately counsel a patient who has been prescribed a medication to treat dyslipidemia.
8. Identify areas of the guidelines that might change with new information received from current literature.
9. Given a patient with dyslipidemia, develop an evidence-based pharmaceutical care plan that includes the goals of therapy, specific medication, dose and duration, monitoring parameters and important counseling points.
10. Recommend adjustment to a patient's lipid lowering therapy based on their reaction to the medication.